Quthero welcomes Dr. Omar Ibrahimi as Chief Medical Director
Quthero, a pioneering biotech company renowned for its unique Q-peptide platform technology, welcomes Omar Ibrahimi, MD,
PhD, a world-renowned dermatologist, to the Quthero team as their Chief Medical Director.
Quthero, a pioneering biotech company renowned for its unique Q-peptide platform technology, proudly announces the
successful acquisition of $500,000 in investment funding from the Ontario Centre of Innovation’s (OCI) Life Science Innovation
Fund. This is in addition to a co-investment of $850,000 for a total round size of $1,350,000.
06.21.2023
Quthero’s clinical advisor, Dr. Catherine DiGiorgio, was selected as one of America’s best cosmetic
dermatologists in Newsweek Magazine for the second year in a row
Quthero is pleased to announce that our Clinical Advisor, Dr. Catherine DiGiorgio of CMD Dermatology, Laser & Aesthetics in
Boston, has been selected as one of America’s Best Cosmetic Dermatologists in Newsweek Magazine for the end year in a row.
04.16.2023
Quthero’s clinical trial and results are presented at 2023 American Society for Laser Medicine and
Surgery Meeting
Quthero is pleased to announce the presentation of its multi-site, split-face double-blinded clinical trial and results with its
proprietary Q-peptide products following aesthetics procedures at the American Society for Laser Medicine and Surgery Meeting.
01.27.2023
Quthero presents at 2023 Aesthetics Tech Forum
Quthero is pleased to announce its presentation at an invitation-only session titled “Partnership Pursuits” on Thursday, January
27th at the Octane’s Aesthetics Tech Forum in Newport Beach, CA.
01.26.2023
Q-gel preclinical studies and initial clinical trial results are presented at 2023 John A. Boswick Burn
and Wound Symposium
Quthero is pleased to announce the presentation of pre-clinical studies with its proprietary Q-gel and clinical trial results at the
John A. Boswick Burn and Wound Symposium taking place at Wailea Beach Resort, Maui, Hawaii.
01.09.2023
Quthero attends the 2023 Biotechnology Showcase at JPM week in San Francisco
Quthero is pleased to announce the opportunities to partner during the upcoming JPM week in San Francisco as our CEO, Dr.
Milica Radisic, attends the Biotechnology Showcase, the investor conference for innovators. Quthero thanks the Government
of Ontario for its support of this opportunity.
12.08.2022
Quthero exceeds the first closing of its Series A round
Quthero is pleased to announce the first closing of its Series A round led by Boston Harbour Angels. The funds will be used to
support the launch of its dermatological post-procedure products and the establishment of a surgical trial.
10.12.2022
Quthero’s CEO, Dr. Milica Radisic, was elected Fellow of the Biomedical Engineering Society
Join Quthero in congratulating our CEO, Dr. Milica Radisic, on being elected a Fellow of the Biomedical Engineering Society
(BMES). BMES serves as the lead society and professional home for biomedical engineers and bioengineers.
09.16.2022
Quthero to present at the RESI Boston Innovator’s Pitch Challenge
Join Quthero at the RESI Boston Conference as we pitch at the Innovator’s Pitch Challenge. Life Science Nation’s Redefining
Early Stage Investments (RESI) is an ongoing conference series establishing a global circuit for early-stage life sciences
companies to source investors, create relationships, and eventually, get funding.
08.31.2022
Quthero welcomes Karen Cronholm as Chief Business Officer
Join Quthero in welcoming Karen Cronholm to the team as the Chief Business Officer. Karen brings 25 years’ experience in the life
sciences, medical device and aesthetics industries, most recently as CEO of Cytrellis Biosystems. She has an exceptional track
record of launching successful products and building commercial teams both at Cytrellis as well as Cynosure and EMD Millipore.
05.04.2022
Quthero launches Series A round led by Boston Harbor Angels
Quthero is pleased to announce that it launched a $2M Series A round, which will be led by Boston Harbor Angels. Boston Harbor
Angels is recognized for fostering innovation and economic growth by bridging the gap between promising startups and
experienced investors. The group’s support has been instrumental in the success of many groundbreaking ideas and ventures.
04.27.2022
Dr. Milica Radisic received the 2022 Acta Biomaterialia Silver Medal
Join Quthero in congratulating our CEO, Dr. Milica Radisic, as the recipient of the 2022 Acta Biomaterialia Silver Medal. Dr. Radisic is
being recognized by Acta Biomaterialia for her contributions in the field of organ-on-a-chip engineering, and hydrogel and
polymeric development.
04.15.2022
Quthero welcomes Kristin King as Business Development Advisor
Join Quthero in welcoming Kristin King, MBA, as Business Development Advisor to the team. Kristin, currently the Vice President,
Corporate Development & Strategy at Defibtech LLC, brings 25 years’ experience in corporate strategy, M&A and business
development in medical devices and pharma.
04.05.2022
Dr. Milica Radisic’s first company, TARA Biosystems, is acquired by Valo Health
Join Quthero in congratulating our CEO, Dr. Milica Radisic, as her first start-up, TARA Biosystems, is acquired by Valo Health.
TARA Biosystems uses tissue engineering to generate in vitro testing systems that mimic cardiac function and disease. These
systems are used for drug discovery as an early predictor for drug safety and toxicity.
03.21.2022
Quthero’s technology has been demonstrated to combat complications from COVID-19 infections
Research from the Radisic Lab at the University of Toronto has identified Quthero’s technology as a potential treatment for COVID-
19. It has shown the ability to prevent cytokine storms, the life-threatening immune reactions linked to severe COVID-19 outcomes.
Quthero is excited to expand the applications of our platform technology.
02.09.2022
Quthero to present at the OBIO Investment summit
Join Quthero at the OBIO Investment Summit as we pitch to kick off our Series A Raise. OBIO’s Investment Summit brings together
leading global investors, scientific experts, and Canada’s most promising health science companies between February 9 and 11.
01.10.2022
Quthero receives medical device designation from Health Canada
In a pivotal decision, Quthero receives Class IV medical device designation for our novel biomaterials for acute donor site wound
healing.
11.12.2021
Quthero welcomes Stephen Whitehead and Wendy Hill as advisors
Join Quthero in welcoming Stephen Whitehead and Wendy Hill as Business and Regulatory Advisors to the team. Stephen
Whitehead brings 25 years of experience in product strategy, development and commercialization. Wendy Hill has over 30 years of
experience in regulatory affairs and clinical trial development in the fields of wound care, inflammation, cancer, and CVD.
Join us in welcoming our clinical advisors! Dr. Miller, founder of the Boston Center for Facial Rejuvenation, is board-certified in
plastic surgery. Dr. DiGiorgio, a Harvard-trained dermatologist, specializes in lasers and cosmetics at the same center. Dr. Ibrahimi,
founding medical director of the Connecticut Skin Institute, is also board-certified in dermatology.
01.20.2022
Quthero to present at Octane OC Aesthetics Tech Summit
Join Quthero at Octane OC Aesthetic Tech Summit where we will pitch our novel biomaterial solutions to disrupt skin care after
dermatological procedures such as laser skin resurfacing & microneedling, and hear from other top leaders in the field of
aesthetics.
Quthero accepted into the prestigious MaRS - adMare Therapeutics Accelerator
Quthero, a biotech company with a unique, patented Q-peptide platform technology, was accepted into the MaRS – adMare
Therapeutics (Tx) Accelerator which provides a distinctive ecosystem for the development of novel therapeutics in Ontario and
Canada. Quthero’s technology enables and accelerates the full regeneration of a patient’s natural tissue with minimal scarring.
11.07.2024
Quthero’s CEO, Dr. Milica Radisic, was the receipient of NSERC’s John C. Polanyi Award
Join Quthero in congratulating our CEO, Dr. Milica Radisic, on receiving Natural Sciences and Engineering Research Council of
Canada (NSERC)’s John C. Polanyi Award. This award is given to an individual or team whose research has led to a recent
outstanding advance in any NSERC-supported field of the natural sciences or engineering.
01.07.2025
Quthero accepted into Innovation Factory’s Founders Fast Track Program
Quthero, a biotech company with a unique, patented Q-peptide platform technology, is pleased to announce acceptance into
Innovation Factory’s Founders Fast Track program, a 6-week training program that covers topics such as customer
development, pitch preparation, funding strategies, and market trends.
02.05.2025
Quthero attended the OBIO Investor Summit 2025
Quthero is pleased to announce its attendance at the OBIO Investor Summit (OIS) 2025, where the CEO, Dr. Milica Radisic, will be
presenting the latest asset development in cardiac health. OIS was created to bring together top Canadian research institutions,
global investors, and innovators in the life sciences.
04.02.2025
Quthero’s CEO, Dr. Milica Radisic, was elected as a fellow of the AAAS
Quthero is immensely proud of its CEO & Founder, Dr. Milica Radisic, as she has been elected a fellow of the American
Association for the Advancement of Science (AAAS), the world’s largest general scientific society, due to her “distinguished
contributions to the field of organ-on-a-chip engineering, particularly for innovation in human cell-based platforms to study the
physiological effects of chemicals on human tissues and organs.”
Get in touch
Mailing Address
Email Address
Quthero Canada Ltd., MaRS Discovery District, 101 College Street,
Suite O-213, Toronto, Ontario, M5G 1L7
Quthero Inc., 100 Bayview Drive, Suite 819, Miami, Florida. 33160